This Drink May Lower Your Dementia Risk by 25%, New Study Says
Drinking 2.5 cups of green tea per day was associated with a 25% reduced risk of dementia.
Other foods with the same antioxidants as green tea include dark chocolate and berries.Brain health has become a popular topic as scientists continue to study the brain in more depth. And while there is still much to learn about the brain, one thing we do know is that dementia is on the rise. We recently reported on a study that suggests that new dementia cases may double from half a million to a million per year by the year 2060. Since we know more about the brain and how to take care of it than we did just a few years ago, this estimation is pretty astonishing.
Dementia is a general term for a loss of memory, language, problem-solving skills and other abilities that are severe enough to interfere with everyday life. Alzheimer's disease is the most common type of dementia.
We know that nutrition plays a large role in brain health. There's even a diet designed specifically to provide brain-healthy nutrients, called the MIND diet. Scientists also consider specific foods to see if there is any correlation between them and decreased disease risk. This is what researchers from Japan did regarding green tea and dementia risk. They recently published their findings in The Journal of Nutrition, Health and Aging. Let's break down what they found.
Researchers drew data from a long-running Japanese study called the Murakami study. This study included 13,660 people, about 52% women with an average age of 59.
Some of the demographics adjusted for during statistical analysis included sex, age, BMI, physical activity, smoking status, alcohol consumption, education level, marital status and medical history. Participants also filled out food frequency questionnaires asking how much and how often certain foods and beverages were consumed, including tea and coffee. Baseline data was collected between 2011 and 2013, and the average follow-up time for each participant was 11.5 years.
For tea and coffee, participants were given the following options for their intake: <1 cup per week, 1-2 cups per week, 3-4 cups per week, 5-6 cups per week, 1 cup per day, 2-3 cups per day, 4-6 cups per day, 7-9 cups per day, and 10 cups per day. Options were also given for canned and bottled tea and coffee, and amounts were calculated into the total intake.
It's important to note that 'a cup' can be interpreted as different amounts in studies and, in this case, is not equal to our American-sized measuring cup. For this reason, researchers calculated consumption into milliliters per day and then placed participants into one of four quartiles (categories). Q1 drank <94 mL of green tea per day, Q2 drank 94-299 mL/day, Q3 drank 300-599 mL/day and Q4 drank ≥ 600 mL/day.
Because they were looking specifically for associations between tea and dementia risk, researchers also gathered data regarding dementia from Japan's long-term care insurance (LTCI) database. In the LTCI, physicians assess the degree of dementia and classify patients into six ranks ranging from no dementia (0) to severe dementia-related behavioral impairment and cognitive impairment requiring treatment (V)—basically using Roman numerals, plus the number 0. Those with rank II (moderate dementia-related behavioral disturbances and cognitive dysfunction with mild dependence) or higher are considered to have dementia.
After running statistical analyses, researchers found that those in the higher quartiles for green tea intake had a lower risk of dementia. Specifically, those in the highest quartile, who drank at least 600 mL (or 20 fluid ounces) per day, had a 25% lower risk of dementia compared to those in the first quartile.
They also broke it down by cups of green tea consumed. Participants saw about a 5% reduction in dementia risk for each cup increase in green tea. For example, if someone averaged a cup of green tea a day, they may decrease their risk of dementia by 5%. For someone who drinks 2 cups a day, the reduction in risk goes to 10%. Keep in mind, though, that these cups are not what we consider a measuring cup amount—they're actually closer to about ½ cup. As an example, Q4 drank at least 600 mL of green tea a day, which is equal to about 2.5 American measuring cups, and reduced their risk of dementia by 25% compared to those in Q1.
Because there is some evidence that coffee may decrease dementia risk, researchers were curious to know if those who drank both coffee and green tea might lower their risk even more. Turns out, unlike those who drank a lot of green tea, adding high levels of coffee in addition to green tea did not have the same effects as green tea alone, and showed no reduction in dementia risk.
Researchers propose a couple of possible reasons for this. First, drinking both green tea and coffee in high doses might have a sort of overdose effect, especially regarding caffeine. As an example, green tea contains 20 mg of caffeine per 100 mL dose, and coffee contains 60 mg of caffeine for the same amount. During the combined portion of this trial, participants in Q4 consumed at least 600 mL/day of green tea and 300 mL/day of coffee, which averages out to 300 mg of caffeine per day. And some were drinking well beyond these amounts. The current recommendation for caffeine is no more than 400 mg/day, so those in Q4 were definitely near or beyond that amount.
Researchers also note that coffee and tea contain different plant compounds and that they may counteract each other. But they seemed to lean more into the caffeine theory.
There are a few limitations to this study. One is that participants' cognitive status was not assessed at baseline. So there's a chance that those who had lower cognitive function at the start of the study drank less green tea. If this is true, then the association between green tea and reduced risk of dementia would be weaker. Also, because green tea consumption was estimated based on self-reports, it leaves room for bias and inaccuracies. Lastly, the type of dementia wasn't investigated, so they can't say which types of dementia green tea may reduce. Researchers do note, however, that because it's estimated that Alzheimer's disease makes up about two-thirds of dementia cases, green tea may help reduce the risk of Alzheimer's.
All types of true teas—green, black, white and oolong—are loaded with antioxidants. They are, after all, plants, and all plants contain antioxidants. But compared to the others, green tea has been shown to have the highest levels of catechins, a specific type of flavonoid antioxidant, providing about four times more catechins than black tea. One of these catechins is epigallocatechin3-gallate (EGCG), which researchers note in previous studies has been linked to reduced Alzheimer's risk. Reasons for this may be due to EGCG's ability to reduce inflammation, including in the brain, plus reduce amyloid-beta and tau-tangle accumulation, both of which are implicated in Alzheimer's disease.
That's not to say that other teas don't have their own benefits. For example, black tea may help you live longer, and ginger tea can help ease an upset stomach and reduce arthritis pain. Mint tea has been shown to have digestive, respiratory and mental health benefits, as well as antimicrobial and antiviral properties.
Besides brain health, green tea has also been associated with lower inflammation, better digestion, less bloating, improved blood sugar and cholesterol levels, and reduced risk of cancer.
It's easy to add green tea to your life. Simply brew up a cup. Ideally, we recommend using loose-leaf tea and steeping it in a tea strainer. The reason for this is that some tea bags have been shown to contain microplastics. These tiny particles may end up steeping from the bag into your cup of tea and ultimately into your body, including your brain. If you're looking to limit your microplastic exposure, a tea strainer may be the best steeping option.
Plain green tea is best, but adding a small amount of honey or sugar or a touch of milk is fine if that's how you prefer it. Just be mindful of how much you add, since too much added sugar has been associated with worse brain health, including dementia. If you want to get to zero additions in your tea, take your usual amount of sweetener and/or cream and begin reducing that amount each week until you're at nothing but the tea. Doing this gradually will help your taste buds adjust. It's also important to point out that the longer you steep your tea, the more bitter it's likely to become. If you don't care for the bitterness, go with shorter steeping times.
If you're not a tea drinker (and even if you are) and want the benefits of catechins, there are a few options for you. Dark chocolate, cherries and berries, including blackberries, raspberries and strawberries, are rich in these powerful plant compounds. Dark chocolate and walnuts make a great brain-healthy snack. And cherries and berries are amazing in smoothies, including our Cherry-Mocha Smoothie, Raspberry-Kefir Power Smoothie and our Berry-Green Tea Smoothie, which provides catechins from both berries and green tea.
If you're ready to really dive into eating for brain health, then you'll want to try our 30-Day MIND Diet Meal Plan for Cognitive Health or our Simple 7-Day Cognitive Health Meal Plan.
This study suggests that higher consumption of green tea is associated with reduced risk of dementia, compared to those with little to no green tea intake. Other lifestyle habits also contribute to brain health, including overall diet, physical activity, managing stressors and getting plenty of quality sleep. If this feels overwhelming and you're not sure where to start, choose an area you're likely to have success in. Adding a couple of cups of green tea each day could be an easy addition and starting point.
Read the original article on EATINGWELL
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
39 minutes ago
- Bloomberg
Pop Mart, Health-Care Stocks Lead Hang Seng Index Contenders
Hang Seng Indexes Co. is likely adding Labubu doll-maker Pop Mart International Group Ltd. and several health-care firms to its Hong Kong stock benchmark, analysts say. Pop Mart has been a frequent contender for inclusion in the Hang Seng Index, with its market capitalization more than tripling this year amid strong demand for its toys and figurines. Health-care stocks have also gained momentum, driven by breakthroughs and overseas partnerships that have lifted sector performance. The results of the quarterly review are expected to be released after the market closes on Friday.


Medscape
5 hours ago
- Medscape
Pricey Drugs Unlikely to Solve Dementia
This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener from the faculty of medicine at the University of Duisburg-Essen, in Germany. In this month's video, I would like to concentrate on the topic of dementia. We made tremendous progress in the diagnosis of Alzheimer's disease, not only at a time when patients show symptoms but also in the preclinical phase of the disease. Biomarkers and Lifestyle We have new biomarkers in cerebrospinal fluid with amyloid and tau PET, and more recently, we have now biomarkers in plasma. One is p-tau217, and this has shown a high sensitivity for the diagnosis of Alzheimer's disease and a good correlation with cerebrospinal fluid markers, as published recently in Neurology . A second aspect is we know that there are about 14 different lifestyle factors and comorbidities that increase the risk for mild cognitive impairment, dementia, and in particular, Alzheimer's disease. The most frequent ones — as you know — are vascular risk factors, hearing loss, smoking, high alcohol intake,obesity, and nutrition. Unfortunately, for most of these correlations, there have been no prospective randomized trials to show that management or treatment of these risk factors or comorbidities would really decrease the risk of Alzheimer's disease. Just to give you an example, there is one study from the US published in Neurology with more than 100,000 participants, and they showed that consumption of red meat significantly increases the risk of dementia. We have in the past not really considered lifestyle factors enough to prevent Alzheimer's disease. Herpes Zoster and Cognitive Impairment There are very interesting findings on the correlation between Herpes zoster and the increased risk of cognitive impairment and have now several studies with hundreds of thousands of patients in the US, in the UK and Australia, which showed that, if someone has Herpes zoster infection, over the next 13 years, the risk of dementia is increased between 15% and 30%. The more interesting feature is that obviously vaccination against Herpes zoster reduces the risk of have been several studies, including one in Wales with almost 300,000 participants. When the vaccination was introduced, participants born before 1933 were not vaccinated, while 50% of those born after 1933 were vaccinated. After 7 years, the diagnosis of dementia was reduced by 3.5% in vaccinated relative risk reduction for dementia was 20%. Another aspect is which vaccine. The study from the United States with more than 100,000 people observed over 6 years showed that recombinant vaccine is more effective in preventing cognitive impairment and dementia compared to the traditional live vaccine. The risk reduction was 17%. GLP-1 Drugs and Anti-Amyloids We have a totally new class of medicines to treat diabetes and obesity: the GLP-1 receptor agonists. There is indirect evidence that they might also be beneficial for the prevention of dementia. One publication in JAMA Neurology looked at a database of more than 33,000 patients treated with GLP-1 receptor agonistsand 34,000 treated with SGLT2 inhibitors compared with standard therapy. For both substances, there was a 35%-45% reduction in the risk of Alzheimer's dementia and other dementias compared to standard therapy. This has to be shown in one of the ongoing trials with GLP-1 receptor agonists. Let me mention the new beta-amyloid antibodies, lecanemab and donanemab. They have been approved both in the United States and in Europe for the treatment of early stages of Alzheimer's disease. This is a complicated business because you need biomarkers and amyloid PET for the diagnosis, you need regular intravenous administration, and you need MR controls to check for Amyloid-related imaging abnormalities. At the recent Alzheimer's Congress in Toronto, for both substances, long-term data were presented for a time period of three to 4 years. They showed that with increasing time of treatment, there is also an increase, obviously, in efficacy if the data are compared with a database, not within the randomized trials, because these were open-label, long-term studies. With donanemab, it was interesting that, in more than 75% of the patients, there was no longer amyloid detected on PET. The other important issue is that there is now a new application of donanemab that is subcutaneous. Spend Money on Lifestyle At the end of the day. I'm not really sure whether this is an effective treatment if we consider cost and risk, and I think a healthcare system would be better advised to invest all this money into teaching of at-risk persons, in particular, to have an impact on lifestyle. I'm aware that, in low-income people, this is extremely difficult, because they cannot afford healthy food and they cannot afford to pay for a gym for regular exercise. I think we can do much better, in particular, in treating comorbidities like obesity, diabetes, hypertension, high cholesterol, and so on. Dear colleagues, this is a short update on what has happened recently in the field of dementia. I'm Christoph Diener from the University of Duisburg-Essen Medical School. Thank you very much for listening and watching.

Associated Press
7 hours ago
- Associated Press
Jupiter Neurosciences CEO And President Talk About The Power of JOTROL And The Launch of Its Longevity Consumer Line With Benzinga
By Meg Flippin Benzinga DETROIT, MICHIGAN - August 21, 2025 ( NEWMEDIAWIRE ) - Christer Rosen, Chairman and CEO, and Alison Silva, President and CBO at Jupiter Neurosciences Inc. (NASDAQ: JUNS), sat down with Benzinga to discuss how the company is addressing longevity and brain health with JOTROL(TM) and its new direct-to-consumer product line, Nugevia. Jupiter Neurosciences is a clinical-stage pharmaceutical company developing JOTROL, an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects. Resveratrol also activates PARP-1 – an important protein in DNA repair and stress response – improves cardiovascular health, enhances cognitive function, is antibacterial and antiviral against food-borne pathogens. JOTROL is designed and intended to deliver therapeutically relevant, safe levels of resveratrol. Meanwhile Nugevia leverages JOTROL to improve mitochondrial support, mental clarity and 'beauty from within.' 'You can drink 10,000 bottles of red wine per day or take two of our capsules,' to get the resveratrol benefits, Rosen told Benzina during the interview. 'The trick is to get enough in the bloodstream, and the existing products don't do the job. JOTROL is patented all over the world through 2036. We are starting to conquer what we think is going to be a fantastic time for us.' How JOTROL Stands Out While resveratrol has been around for decades and is among the most researched molecules, Silva says achieving therapeutic benefits has proven elusive, mainly due to dosing limitations. To achieve therapeutic benefits, the plasma concentration has to be over 250 nanograms per milliliter, and to get that amount into a product would be impossible without having either severe gastrointestinal (GI) side effects or having to swallow a lot of huge pills. Jupiter Neurosciences was able to reformulate resveratrol and, through clinical trials, demonstrated blood plasma levels 8-10-fold higher than naïve resveratrol with one-tenth the dose. Plus, there were no GI side effects. 'It makes it a key therapeutic for inflammation in the neurodegenerative space, inflammation in the longevity and healthspan space,' said Silva. 'So that's the cracking of the code we believe we have done with JOTROL.' Leveraging JOTROL For The Consumer Market In addition to developing JOTROL to treat central nervous system (CNS) disorders such as Alzheimer's, Parkinson's and rare diseases, the company just launched a direct-to-consumer line, Nugevia, which leverages JOTROL. The idea came to Jupiter Neurosciences about a year ago when the longevity and aging market was getting a lot of attention. Lots of companies were making claims about having supplements backed by clinical data, but the majority, says Rosen, didn't really have the clinical proof – but Jupiter Neurosciences did. 'We're definitely ahead of the curve. We already have a product going into a Parkinson trial, and at the same time, we said why don't we launch a nutraceutical line and have some cash flow. I happened to like cash flow. Biotech is not cash flow,' said Rosen. Nugevia's first three formulations, which it just launched, target mitochondrial support, mental clarity and 'beauty from within' and will be sold via a direct-to-consumer (DTC) model. Nugevia GLO is a daily supplement designed to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity and hydration. Nugevia PWR is a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance and recovery, and Nugevia MND is a scientifically formulated supplement designed to protect and enhance cognitive function and support overall brain health. All three will be available direct-to-consumers in September. Short Sellers Be Forewarned As for when Jupiter Neurosciences will see revenue from its Nugevia product line, Rosen said it will start to materialize this year, next year and more meaningfully in the year after that, once it has more brand ambassadors and key opinion leaders on board and word is out about its products. Jupiter already announced professional golfer Annika Sörenstam – who has won over 95 international tournaments including 72 LPGA titles and 10 major championships – is the company's first brand ambassador, and more will be announced soon. Rosen said potential spokespeople are drawn to the company because of the science behind its products. 'The market doesn't know about it yet, when you look where we are with the stock price,' says the CEO. 'We've been hit by short sellers heavily…we took it as we need to deliver, and when we deliver the share price will take care of itself, and that's what we plan to do and do it sooner than people expect.' Featured image fromShutterstock. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. This content was originallypublished on further disclosureshere.